Skip to main content
BRKR logo

Bruker Corporation (BRKR) Stock: Price, Forecast & Analyst Target

Bruker Corporation (BRKR) — MoonshotScore 59/100 (Fair band), calculated Nov 18, 2026. Price $62.10 (-1.83%), as of the Nov 19, 2026 trading session; market cap $9.48B. Expected results Feb 11, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 56.77× (cash as of Sep 30, 2026) · expected results Feb 11, 2027

$62.10 −$1.16 (-1.83%) Market Cap $9.48B

Bruker Corporation · BRKR · NASDAQ · Healthcare · Medical - Devices

Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered): Bruker sells scientific instruments, diagnostic platforms, nanoscale and semiconductor metrology tools, plus superconducting materials and systems; it is much broader than a conventional medical-device manufacturer. The case depends on whether this product-heavy portfolio can turn growing sales into dependable margins and cash generation while debt remains far above cash.

Price as of Nov 19, 2026

Key Statistics

59 of 100

MoonshotScore v2 · Bruker (BRKR)

Fair
Business Quality Solid (71)
Financial Safety Fragile (15)
Valuation Full (45)
Growth Durability Fading (35)
Momentum Surging (90)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet, weak growth and a full valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Surging.

  • quarterly revenue $874M (Q3 FY2026, quarter ended Sep 2026)
  • EPS beat 6 of the last 8 reports
  • Altman Z 2.89 · Piotroski F 5

Holding back: balance-sheet strain

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BRKR (57 recorded, newest six shown)
RecordedScoreBand
57Fair
58Fair
58Fair
58Fair
59Fair
59Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$62.10
Change on the day-1.83%
52-week range$32.37–$68.98
Market capitalisation$9.48B—
Shares traded on the day1.84M
Beta (volatility vs the S&P 500)1.26
Dividends per share (last 12 months)$0.20
Dividend yield (last 12 months)0.33%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $33, high $64, latest $62. 4 reported quarters marked, 3 above and 1 below the recorded estimate. 1 other dated event marked. $64 $33 high $64 Feb 12, 2026 · Earnings results · reported below the recorded estimate · close $371May 6, 2026 · Earnings results · reported above the recorded estimate · close $442Aug 4, 2026 · Earnings results · reported above the recorded estimate · close $533Nov 4, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $614Nov 4, 2026 · Earnings results · reported above the recorded estimate · close $615 Oct 17, 2025 Nov 19, 2026 · $62 $37Oct 17, 2025$39Oct 31, 2025$42Nov 14, 2025$49Nov 28, 2025$45Dec 12, 2025$48Dec 26, 2025$54Jan 9, 2026$50Jan 23, 2026$42Feb 6, 2026$38Feb 20, 2026$37Mar 6, 2026$33Mar 20, 2026$37Apr 2, 2026$41Apr 17, 2026$37May 1, 2026$43May 15, 2026$59May 29, 2026$54Jun 12, 2026$61Jun 26, 2026$60Jul 10, 2026$60Jul 24, 2026$53Aug 7, 2026$60Aug 21, 2026$59Sep 4, 2026$61Sep 18, 2026$63Oct 2, 2026$55Oct 16, 2026$57Oct 30, 2026$62Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • While the lead times on these orders are longer than most of our life science tools, we expect to see these semi orders convert into revenue mostly in fiscal year 2027 and some in fiscal year 2028.

    Frank Laukien · Statement from

  • We now expect currency to be approximately neutral to reported revenue for fiscal year 2026 after the recent strengthening of the U.S. dollar. We continue to expect non-GAAP operating margin expansion of 250-300 basis points year over year, largely driven by our cost-saving actions.

    Gerald Herman · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Bruker (BRKR): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Neutral
Growth Durability Weak
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Weak
ROE Negative
Gross Margin Moderate

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Bruker (BRKR), and what does it report?

Short answer · as of

Laboratories, drug and biomarker researchers, microbiology users, semiconductor customers, and advanced-research facilities buy Bruker systems for measurement, identification, imaging, process control, and materials work.

Revenue therefore reflects shipments across capital equipment, analytical tools, diagnostics, superconducting materials, and related services rather than a narrow stream of patient-facing medical devices.

Reporting groups the business around life-science instrumentation, nanoscale tools, and energy and superconducting technologies. Product sales dominate the disclosed revenue split, leaving reported sales sensitive to instrument demand and customer delivery schedules.

2 · Latest results

What do the latest results show for Bruker (BRKR)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $874M.

Latest revenue improved from the preceding period and the comparable period, while gross profit also rose. Yet operating and net results swung into loss, and operating cash flow turned negative, so the sales improvement did not translate into accounting or cash profitability.

The reported-versus-estimated earnings series cleared consensus even though the income statement showed a loss; those measures need to remain separate. Management says semiconductor customer delivery requirements shifted planned revenue into a later period and expects near-term margin pressure before higher volume and favorable mix support a rebound.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$874.00M Sep 30, 2026
Latest quarter · R&D
$92.00M Sep 30, 2026
Latest quarter · SG&A
$226.50M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$91.00M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$874.00M$92.00M$226.50M−$91.00M
Jun 30, 2026$838.50M$94.30M$238.90M−$65.30M
Mar 31, 2026$823.40M$101.30M$242.10M$45.00M
Dec 31, 2025$977.20M$99.60M$247.20M$111.80M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$874.00M Nov 4, 2026
Latest report · revenue estimate
$865.16M Nov 4, 2026
Latest report · revenue vs estimate
Above estimate Nov 4, 2026
Latest report · EPS vs estimate
Above estimate Nov 4, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 4, 2026$874.00M$865.16M$0.5600$0.4190
Aug 4, 2026$838.50M$853.57M$0.4900$0.3849
May 6, 2026$823.40M$795.62M$0.3100$0.2300
Feb 12, 2026$977.20M$962.26M$0.5900$0.6500
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$874M-$112M-$0.81 (diluted)
Q2 FY2026$839M-$52M-$0.41 (diluted)
Q1 FY2026$823M$14M$0.02 (diluted)
Q4 FY2025$977M$26M$0.10 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Bruker (BRKR)?

Short answer

Cash and short-term investments were $167.00M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $118.20M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Bruker retains meaningful gross profit and current assets exceed current liabilities, but the stricter near-cash liquidity measure falls short of full coverage. Annual sales have expanded while net income deteriorated into loss, showing that commercial growth has not protected the bottom line.

Debt greatly exceeds cash and short-term investments, while operating cash flow has alternated between positive and negative periods despite recurring capital expenditure. Product concentration and substantial research, selling, and administrative costs create operating leverage in either direction: delayed deliveries can leave the expense base exposed, while favorable volume and mix can lift profitability.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$118.20M Sep 30, 2026
Previous quarter · operating cash flow
−$77.40M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$118.20M−$21.50M
Jun 30, 2026−$77.40M−$28.80M
Mar 31, 2026$71.20M−$24.20M
Dec 31, 2025$229.80M−$22.60M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Bruker (BRKR)?

Short answer · as of

The next earnings report is expected on Feb 11, 2027.

Semiconductor deliveries are the immediate checkpoint. Compare the scheduled earnings release with management’s expectation that shifted revenue returns alongside better volume, mix, organic growth, operating margin, and earnings.

Beyond sales, watch for operating cash flow to recover, losses to reverse, and cash to strengthen relative to debt. Longer-range analyst estimates assume continued revenue and earnings expansion, but firm ratings remain dispersed; Bruker’s own cash conversion and margin progression provide the more useful test.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. We expect fourth quarter organic revenue to grow in the lower mid-single digits percentage year over year.

    Gerald Herman ·

  2. We expect meaningful sequential and year-over-year increases in operating margin and EPS due to higher volume and favorable mix in the fourth quarter, as well as due to the compounding effects from our cost-saving actions.

    Gerald Herman ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does Bruker compare with its peers?

Short answer

Bruker's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Bruker differs from a typical medical-device peer because its portfolio spans mass spectrometry, microbiology identification, X-ray and atomic-force microscopy, semiconductor metrology, multi-omics tools, and superconducting materials. Customers are buying research, analytical, diagnostic, and industrial capability, not mainly patient-facing devices.

The economic profile remains that of a product-led instrument supplier: product revenue dominates, while a smaller combined category covers other products and services. That mix leaves Bruker more exposed to shipment timing and hardware mix than a service-led business, even though diagnostics and specialized services broaden its demand sources.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Krystal Biotech, Inc. (KRYS) Named competitor$315.34 Nov 18, 2026$9.34B96 5-pillar Nov 18, 2026
Globus Medical, Inc. (GMED) Same industry, near in market value$70.53 Nov 18, 2026$9.34B94 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$320.00 Nov 19, 2026$12.6B92 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Named competitor$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
LivaNova PLC (LIVN) Same industry, near in market value$94.54 Nov 18, 2026$5.21B88 5-pillar Nov 18, 2026
BrightSpring Health Services, Inc. (BTSG) Named competitor$68.34 Nov 18, 2026$13.6B87 5-pillar Nov 18, 2026
STERIS plc (STE) Same industry, near in market value$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Chemed Corporation (CHE) Named competitor$546.72 Nov 18, 2026$7.09B85 5-pillar Nov 18, 2026
Insulet Corporation (PODD) Same industry, near in market value$139.98 Nov 18, 2026$9.71B85 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$30.32 Nov 18, 2026$12.7B84 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Same industry, near in market value$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$103.32 Nov 18, 2026$19.6B79 5-pillar Nov 18, 2026
Bruker (BRKR) — this page$62.10$9.48B59

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$50.00 – $80.00
Consensus target
$67.00
Median target
$70.00

Consensus record · Captured .

Measured against a quoted price of $62.10 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 15, 2026

Transactions
38
Identified insiders
7
Purchases
0
Sales
5
Other transactions
33

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
89.5% Period end Sep 30, 2026
Previous quarter · ownership
94.4% Prior to period end Sep 30, 2026
Reporting holders
449 Period end Sep 30, 2026
Previous quarter · holders
435 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Fmr LLC20,296,294
Orbis Allan Gray Ltd17,940,076
Blackrock, INC.11,789,436
Pallas Capital Advisors LLC9,483,840
Vanguard Portfolio Management LLC4,974,922

Tracked investors

Which of the 16 named investors we follow held BRKR in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.14%$31.59MAdded +1052.3% shares
Viking GlobalAndreas HalvorsenQ3 20260%$0Sold out (was $53.77M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Bruker (BRKR)?

Read these with our analysis →

Bruker Healthcare Stock: Key Questions Answered

The last 3 questions are answered from this page's own dated data, not from the research.

What does the MALDI Biotyper add to Bruker’s business mix?

The MALDI Biotyper gives Bruker exposure to rapid pathogen identification within a portfolio otherwise rich in research and analytical instruments. Microbiology diagnostics therefore contribute a distinct demand stream without making Bruker a conventional patient-device company.

Why do semiconductor delivery requirements move Bruker revenue?

Bruker sells metrology and defect-detection equipment whose reported revenue can depend on customer delivery timing. Management said semiconductor requirements shifted planned sales between reporting periods, with related effects on expected margins and earnings.

Why has Bruker’s rising revenue not produced stronger profit?

Research, selling, and administrative costs remain substantial, and recent gross profit did not prevent operating and net losses. Cash generation has also been uneven, showing that higher sales have not consistently converted into profit or cash.

How does Bruker Energy and Supercon Technologies change the company’s exposure?

The segment adds superconducting materials, devices, and beamline or synchrotron instrumentation to the life-science and nanoscale portfolio. This introduces advanced-research and energy-related demand that a medical-device label would not imply.

What is the BRKR stock price today?

The last price recorded for Bruker Corporation (BRKR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BRKR price target?

The analyst consensus price target for Bruker Corporation (BRKR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Does BRKR pay a dividend?

Yes. The dividend yield of Bruker Corporation (BRKR) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 82 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 3 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions); Cash, investments and debt; Operating cash flow by quarter (USD millions)
  • 1. What is Bruker (BRKR), and what does it report?: Legal name; Business description; Sector / industry (provider taxonomy); Revenue by segment
  • 2. What do the latest results show for Bruker (BRKR)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Most recent periodic reports
  • 3. What are the financial strengths and risks for Bruker (BRKR)?: Trailing twelve-month ratio set; Annual revenue and net result (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Revenue by segment; Management outlook — dated call excerpts
  • 4. What should you watch next at Bruker (BRKR)?: Next earnings report; Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Analyst revenue and earnings estimates (average); Analyst actions, most recent per firm
  • 5. How does Bruker compare with its peers?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Management outlook — dated call excerpts
  • FAQ: What does the MALDI Biotyper add to Bruker’s business mix?: Business description; Sector / industry (provider taxonomy)
  • FAQ: Why do semiconductor delivery requirements move Bruker revenue?: Business description; Management outlook — dated call excerpts; Quarterly income statement (USD thousands)
  • FAQ: Why has Bruker’s rising revenue not produced stronger profit?: Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • FAQ: How does Bruker Energy and Supercon Technologies change the company’s exposure?: Business description; Sector / industry (provider taxonomy)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.